Greencare Capital - Grant of Options
Announcement provided by
MaxRets Ventures Plc · MAX01/07/2021 11:00
Greencare Capital plc
("Greencare" or the "Company")
Grant of options
Greencare (AQSE: GRE), the investment company focused on investing in CBD and related wellness areas, announces that it has adopted a new unapproved Employees' Share Scheme (the "2021 Scheme") and made a grant of share options to a director. The 2021 Scheme supplements the Company's share option scheme adopted in May 2020 (the "2020 Scheme").
The vesting conditions and key terms of the 2021 Scheme are identical to the 2020 scheme, save for the exercise price and eligible participants. The 2021 Scheme and 2020 Scheme provide that options may be issued over a maximum of 10 per cent. of the Company's issued share capital in aggregate across both schemes, from time to time, and up to a maximum of 200 per cent. of an employee's annual salary.
The Company has granted options under the 2021 Scheme as follows:
|
Option holder
|
Number of Options Granted |
Exercise Price |
Options Granted as Percentage of Issued Share Capital |
|
Richard Tonthat |
360,000 |
30.5p |
2.4% |
|
|
|
|
|
|
Total |
360,000 |
|
2.4% |
The exercise period for options granted under the 2021 Scheme and 2020 Scheme is three years from the date of grant. The vesting criteria for options granted under both schemes are as follows:
|
Amount Vesting |
Time Condition |
Performance Condition |
|
50 per cent. ("Tranche One") |
On the business day following the first financial year end following the date of grant
|
the NAV on the Tranche One Vesting Date not being less than the NAV on the Grant Date |
|
50 per cent. ("Tranche two") |
On the business day following the second financial year end following the date of grant |
the NAV on the Tranche Two Vesting Date being a minimum of 10% higher than the NAV on the Grant Date |
Vesting conditions may be varied or waived provided that any varied vesting condition shall be a fairer measure of performance, as judged at the time, and no more difficult to satisfy than the original vesting condition. Both schemes provide for good leaver provisions and other standard terms normally associated with such a scheme.
As a result of the grant of options detailed above, the Company has in issue options over 927,272 ordinary shares representing 6.27 per cent. of the Company's issued share capital.
This announcement contains inside information for the purposes of Article 7 of Regulation (EU) No 596/2014 ("MAR"), as in force in the
Enquiries:
|
Greencare Capital plc Richard Tonthat, CEO
|
+44 (0)20 7933 8780 |
|
Cairn Financial Advisers LLP AQSE Corporate Adviser Jo Turner / James Lewis
|
+44 (0)20 7213 0885
|
|
Walbrook PR Limited Paul Vann/Nicholas Johnson
|
+44 (0)20 7933 8780 +44 (0)7768 807631 greencarecapital@walbrookpr.com |
Notification and public disclosure of transactions by persons discharging managerial responsibilities / person closely associated with them.
|
1. |
Details of the person discharging managerial responsibilities/person closely associated |
|||||
|
a) |
Name |
Richard Tonthat |
||||
|
2. |
Reason for the notification |
|||||
|
a) |
Position/status |
CEO, Director |
||||
|
b) |
Initial notification/Amendment |
Initial Notification |
||||
|
3. |
Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor |
|||||
|
a) |
Name |
Greencare Capital plc |
||||
|
b) |
LEI |
213800E5Z6QRDSMZMK84 |
||||
|
4. |
Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted |
|||||
|
a) |
Description of the financial instrument |
Options |
||||
|
b) |
Identification code |
GB00BJBYK814 |
||||
|
c) |
Nature of the transactions |
Grant of Options |
||||
|
d) |
Price(s) and volume(s) |
|
||||
|
e) |
Aggregated information - Aggregated volume - Price |
- 360,000
- 30.5p
|
||||
|
f) |
Date of the transactions |
30 June 2021 |
||||
|
g) |
Place of the transactions |
AQSE Growth Market, |
||||
RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
